Analyst Price Target is $5.41
▲ +214.39% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for IMV in the last 3 months. The average price target is $5.41, with a high forecast of $13.00 and a low forecast of $1.38. The average price target represents a 214.39% upside from the last price of $1.72.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in IMV. This rating has held steady since May 2021, when it changed from a Buy consensus rating.
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.